OpGen – Consensus Indicates Potential 105.2% Upside

DirectorsTalk Interviews

OpGen found using ticker (OPGN) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 7 and 4 calculating the average target price we see 5.5. Now with the previous closing price of 2.68 this would imply there is a potential upside of 105.2%. There is a 50 day moving average of 2.49 and the 200 day moving average is 2.2. The market cap for the company is $85m. Visit the company website at: http://www.opgen.com

OpGen, a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect pathogens in positive blood cultures. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. OpGen has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Share on:

Latest Company News

Innov8 Gases uses new technology to support helium development

Innov8 Gases is applying proprietary electro-seismic technology to support drilling decisions and reduce development uncertainty across its Arizona helium...

Multipanel outlines bathroom trends for autumn and winter 2026

Multipanel identifies three bathroom trends for autumn and winter 2026, featuring warmer colours, natural textures and deeper statement shades....

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Finseta raises £1.57m to support UAE expansion

Finseta has conditionally raised £1.57m through a strategic UAE investment and agreed a referral partnership to expand its international...

James Cropper CEO David Stirling on 90% EBITDA growth and upgraded FY guidance

James Cropper CEO David Stirling discusses higher interim revenue, improved profitability, the return of dividend payments and upgraded full-year...

Drax secures £20bn backing for major UK data centre development

Drax has secured £20bn backing from Qai and Brookfield for a major North Yorkshire data centre, with initial operations...

    Search